Yabao Pharmaceutical Group Co. Ltd.SSE: 600351

Announcement on Convening the Q3 2024 Performance Briefing

Nov 5, 2024 · Issued by Yabao Pharmaceutical Group Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · Nov 5, 2024

On 6ix: 6ix.com/news/announcement-on-convening-the-q3-2024-performance-briefing-19

Announcement on Convening the Q3 2024 Performance Briefing

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Yabao Pharmaceutical Group Co. Ltd. on 6ix

Earlier from Yabao Pharmaceutical

Announcement on Correction of Report for Q3 2024Oct 26, 2024
Report for Q3 2024Oct 25, 2024
Announcement on Obtaining Approval of Phase II Clinical Trial for New Indication of Project SY-009Sep 30, 2024
Announcement on Notice to CreditorsSep 4, 2024
Announcement on Convening 2024 Semi-annual Performance BriefingAug 17, 2024

Later from Yabao Pharmaceutical

Announcement on a Wholly-owned Subsidiary Obtaining One Drug Registration CertificateNov 22, 2024
Announcement on the Termination of the Technology Transfer Agreement for the Traditional Chinese Medicine New Drug ProjectJan 18, 2025
Announcement on the Repurchased Company Shares Reaching 1% and Repurchase ProgressFeb 6, 2025
Announcement on ZY-A001 Obtaining Notice of Approval for Drug Clinical TrialsFeb 15, 2025
Announcement on Implementation Results of Share Repurchase and Share ChangesMar 4, 2025

All Yabao Pharmaceutical news releases

Follow Yabao Pharmaceutical into a list and get an email when it puts out news.

Follow Yabao Pharmaceutical